Necrotic tumor cell death in vivo impairs tumor-specific immune responses

Journal of Immunology

Volumn 178, Issue 3, 2007, Pages 1573-1580

  Gamrekelashvili, Jaba ^a   Krüger, Christine ^a   Von Wasielewski, Reinhard ^a   Hoffmann, Matthias ^a   Huster, Katharina M ^b   Busch, Dirk H ^b   Manns, Michael P ^a   Korangy, Firouzeh ^a   Greten, Tim F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; N ACETYLCOLCHINOL PHOSPHATE; THYMIDINE KINASE;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR NECROSIS;

EID: 33846496939     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.3.1573     Document Type: Article

References (51)

1. Kerr, J. F., A. H. Wyllie, and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26: 239-257.
2. Restifo, N. P. 1996. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8: 658-663.
3. Steinman, R. M., S. Turley, I. Mellman, and K. Inaba. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191: 411-416.
4. Albert, M. L. 2004. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol. 4: 223-231.
5. Skoberne, M., A. S. Beignon, and N. Bhardwaj. 2004. Danger signals: a time and space continuum. Trends Mol. Med. 10: 251-257.
6. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bhardwaj. 2000. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med 191: 423-434.
7. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
8. Restifo, N. P. 2000. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. 12: 597-603.
9. Casares, N., M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. 2005. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202: 1691-1701.
10. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κ B pathway. Int. Immunol. 12: 1539-1546.
11. Beg, A. A. 2002. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 23: 509-512.
12. Reiter, L, B. Krammer, and G. Schwamberger. 1999. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J. Immunol. 163: 1730-1732.
13. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol 12: 991-1045.
14. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13: 114-119.
15. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature 392: 86-89.
16. Kerbel, R., and J. Folkman. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.
17. Micheletti, G., M. Poli, P. Borsotti, M. Martinelli, B. Imberti, G. Taraboletti, and R. Giavazzi. 2003. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res. 63: 1534-1537.
18. Davis, P. D., G. J. Dougherty, D. C. Blakey, S. M. Galbraith, G. M. Tozer, A. L. Holder, M. A. Naylor, J. Nolan, M. R. Stratford, D. J. Chaplin, and S. A. Hill. 2002. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62: 7247-7253.
19. McCarty, M. F., A. Takeda, O. Stoeltzing, W. Liu, F. Fan, N. Reinmuth, M. Akagi, C. Bucana, P. F. Mansfield, A. Ryan, and L. M. Ellis. 2004. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. Br. J. Cancer 90: 705-711.
20. Beerepoot, L. V., S. A. Radema, E. O. Witteveen, T. Thomas, C. Wheeler, S. Kempin, and E. E. Voest. 2006. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol. 24: 1491-1498.
21. Beltinger, C., S. Fulda, T. Kammertoens, E. Meyer, W. Uckert, and K. M. Debatin. 1999. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA 96: 8699-8704.
22. Barba, D., J. Hardin, M. Sadelain, and F. H. Gage. 1994. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91: 4348-4352.
23. Nowak, A. K., B. W. Robinson, and R. A. Lake. 2003. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63: 4490-4496.
24. Emens, L. A., R. T. Reilly, and E. M. Jaffee. 2005. Cancer vaccines in combination with multimodality therapy. Cancer Treat. Res. 123: 227-245.
25. + memory T cell subsets. Proc. Natl. Acad. Sci. USA 101: 5610-5615.
26. Klein, C., H. Bueler, and R. C. Mulligan. 2000. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191: 1699-1708.
27. 2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J. Immunol. Methods 271: 125-135.
28. Scheffer, S. R., H. Nave, F. Korangy, K. Schlote, R. Pabst, E. M. Jaffee, M. P. Manns, and T. F. Greten. 2003. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103: 205-211.
29. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
30. Thomas, M. C., T. F. Greten, D. M. Pardoll, and E. M. Jaffee. 1998. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9: 835-843.
31. Rolink, A., F. Melchers, and J. Andersson. 1996. The SCID but not the RAG-2 gene product is required for S μ-S ε heavy chain class switching. Immunity 5: 319-330.
32. Vakkila, J., and M. T. Lotze. 2004. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4: 641-648.
33. Rovere, P., M. G. Sabbadini, C. Vallinoto, U. Fascio, V. S. Zimmermann, A. Bondanza, P. Ricciardi-Castagnoli, and A. A. Manfredi. 1999. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J. Leukocyte Biol. 66: 345-349.
34. Henry, F., O. Boisteau, L. Bretaudeau, B. Lieubeau, K. Meflah, and M. Gregoire. 1999. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59: 3329-3332.
35. Nowak, A. K., R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. Robinson. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170: 4905-4913.
36. Blachere, N. E., R. B. Darnell, and M. L. Albert. 2005. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3: e185.
37. Reits, E. A., J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K. Wamsley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, et al. 2006. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203: 1259-1271.
38. Starck, L., C. Scholz, T. Blankenstein, B. Dorken, and P. T. Daniel. 2005. Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells. Int. J. Cancer 116: 78-86.
39. Majno, G., and I. Joris. 1995. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146: 3-15.
40. Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434.
41. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335-2342.
42. Willett, C. G., Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, et al. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10: 145-147.
43. Lake, R. A., and B. W. Robinson. 2005. Opinion: Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5: 397-405.
44. Emens, L. A., and E. M. Jaffee. 2005. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65: 8059-8064.
45. Shi, Y., W. Zheng, and K. L. Rock. 2000. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 97: 14590-14595.
46. Shi, Y., J. E. Evans, and K. L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521.
47. Srivastava, P. 2002. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2: 185-194.
48. Masse, D., F. Ebstein, G. Bougras, J. Harb, K. Meflah, and M. Gregoire. 2004. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. Int. J. Cancer 111: 575-583.
49. Rovere, P., G. Peri, F. Fazzini, B. Bottazzi, A. Doni, A. Bondanza, V. S. Zimmermann, C. Garlanda, U. Fascio, M. G. Sabbadini, et al. 2000. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96: 4300-4306.
50. Baruah, P., A. Propato, I. E. Dumitriu, P. Rovere-Querini, V. Russo, R. Fontana, D. Accapezzato, G. Peri, A. Mantovani, V. Barnaba, and A. A. Manfredi. 2006. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood 107: 151-158.
51. Fadok, V. A., D. L. Bratton, D. M. Rose, A. Pearson, R. A. Ezekewitz, and P. M. Henson. 2000. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405: 85-90.